Biological response modifiers (BRM), chemotherapy, and activated cytotoxic leukocyte subsets: strategies for rational design of apheresis-based cancer immunotherapies.

H. C. Stevenson, H. G. Klein

Research output: Contribution to journalArticlepeer-review

Original languageEnglish (US)
Pages (from-to)559-565
Number of pages7
JournalProgress in Clinical and Biological Research
StatePublished - 1990
Externally publishedYes

ASJC Scopus subject areas

  • General Medicine

Cite this